Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing cccdna formation of hepatitis b virus

A technology of hepatitis B virus and its composition, which is applied in the fields of compound screening, biological testing, and biological material analysis, and can solve problems such as blocking HBV replication

Inactive Publication Date: 2018-06-08
GREEN CROSS CORP THE +1
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Any currently used treatment that inhibits HBV genomic DNA replication and thus HBV formation in the blood, however, cannot fundamentally block HBV replication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing cccdna formation of hepatitis b virus
  • Pharmaceutical composition for preventing cccdna formation of hepatitis b virus
  • Pharmaceutical composition for preventing cccdna formation of hepatitis b virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0083] Example: Estimates of the HBV Infection Inhibitory Efficacy of the Human HBV Antibody (GC 1102) against HBsAg Evaluate

[0084]

[0085] 1) Anti-HBsAg antibody: The antibody (GC1102) used in this experiment is a human antibody represented by the following: the amino acid sequence SEQ ID NO: 1 (HBAb-H4 ); and the amino acid sequence SEQ ID NO: 2 (HBAb-L9) encoding the variable region of the human antibody L chain against the surface antigen of HBV.

[0086] 2) Control group: Both a sample treated with IgG as a negative control and a sample treated with Myrcludex B (MyrB) as a positive control in conducting the experiment were prepared so as to minimize the occurrence of experimental errors. MyrB used as a positive control is a lipopeptide consisting of 47 amino acids in the HBsAg Pre-S1 domain and is now in clinical trials as an HBV entry inhibitor.

[0087]3) Cell culture: The HepG2-NTCP cell line used in this experiment is a cell line stably expressing human NTCP ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is based on a finding that a hepatitis B virus antibody inhibits binding of a surface antigen (HBsAg) of hepatitis B virus to heparan sulfate proteoglycan, thereby preventing cccDNA formation of the hepatitis B virus. It is expected that utilizing the pharmaceutical composition and the method of preventing cccDNA formation of hepatitis B virus of the present invention can fundamentally treat chronic hepatitis B and also prevent a recurrence of hepatitis in a hepatitis B patient after liver transplant surgery. Further, according to the present invention, a material for preventing or treating hepatitis B can be newly identified by confirming whether cccDNA formation is inhibited or not. In addition, according to the present invention, a treatment supplement capable of being administered in combination with the hepatitis B virus antibody can be newly identified.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing cccDNA formation of hepatitis B virus. Background technique [0002] Hepatitis B virus (HBV) is a virus having a DNA genome belonging to the Hepadnaviridae family, and induces acute and chronic hepatitis. About 350 million of the world's population are chronically HBV positive, and in particular, Korea and China have about 5 to 8% of chronically infected people. Such chronic HBV infection can induce hepatitis, cirrhosis and even liver cancer. People with chronic infection show about 300 times higher incidence of liver cancer than normal people. According to WHO research, 80% of liver cancer is caused by chronic HBV. [0003] The hepatitis B virus has been partially prevented due to the development of vaccines. However, once HBV has invaded the liver cells, there is no way to completely remove the HBV that has entered the patient's liver cells. Therefore, it is very diffic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395G01N33/50
CPCA61K39/395G01N33/50C07K16/082A61K2039/505C07K2317/21C07K2317/76C07K2317/92G01N33/5067G01N2333/02G01N2500/04
Inventor 张基奂高天奎柳王埴辛庸源
Owner GREEN CROSS CORP THE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com